EPHB2 and neoplasm: Resistance to tyrosine kinase inhibitors of ALK has been described in multiple tumor types and can arise through different mechanisms.1 Here we show that in ALKF1174L-driven NB cells, the development of resistance to TAE684 and its clinically available derivative, LDK378, is associated with AXL overexpression and activation, as well as increased ERK signaling.